ArticleNature communications2018
Efficacy of a respiratory syncytial virus vaccine candidate in a maternal immunization model.
Article in Nature communications, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 48 citations in OpenAlex.
- Intranasal Delivery of an RSV A2-Derived Pre-F VLP Vaccine Induces Robust Mucosal and Systemic Immunity Against RSV B Strain Without Enhanced Disease.Immune network · 2026Article
- A truncated pre-F protein mRNA vaccine elicits an enhanced immune response and protection against respiratory syncytial virus.Nature communications · 2025Article
- Virus-like particles containing the extracellular domain of G protein in combination with a CTL peptide of M2 elicit protection against respiratory syncytial virus infection without pulmonary disease.Frontiers in immunology · 2025Article
- Glycoconjugate vaccines: platforms and adjuvants for directed immunity.Glycobiology · 2024Review
- Design and Preclinical Evaluation of a Nanoparticle Vaccine against Respiratory Syncytial Virus Based on the Attachment Protein G.Vaccines · 2024Article
- Article
- Virus-like Particle Vaccine Expressing the Respiratory Syncytial Virus Pre-Fusion and G Proteins Confers Protection against RSV Challenge Infection.Pharmaceutics · 2023Article
- The Respiratory Syncytial Virus (RSV) G Protein Enhances the Immune Responses to the RSV F Protein in an Enveloped Virus-Like Particle Vaccine Candidate.Journal of virology · 2023Article
- Respiratory Viruses and Virus-like Particle Vaccine Development: How Far Have We Advanced?Viruses · 2023Review
- Correlative outcomes of maternal immunization against RSV in cotton rats.Human vaccines & immunotherapeutics · 2022Article
- Article
- Virus-like particles containing a prefusion-stabilized F protein induce a balanced immune response and confer protection against respiratory syncytial virus infection in mice.Frontiers in immunology · 2022Article
- Immunopathology of RSV: An Updated Review.Viruses · 2021Review
- Evolution of protection after maternal immunization for respiratory syncytial virus in cotton rats.PLoS pathogens · 2021Article
- Transplacental Antibody Transfer of Respiratory Syncytial Virus Specific IgG in Non-Human Primate Mother-Infant Pairs.Pathogens (Basel, Switzerland) · 2021Article
- Article
- Article
- Virus-Like Particle Vaccines Against Respiratory Viruses and Protozoan Parasites.Current topics in microbiology and immunology · 2021Review
- Aging and Options to Halt Declining Immunity to Virus Infections.Frontiers in immunology · 2021Review
- Adjustable Algorithmic Tool for Assessing the Effectiveness of Maternal Respiratory Syncytial Virus (RSV) Vaccination on Infant Mortality in Developing Countries.Infectious diseases in obstetrics and gynecology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
Abstract
Respiratory syncytial virus (RSV) is the most common cause of bronchiolitis in infants. Maternal immunization is an option to increase maternal antibody levels and protect infants from infection. Here we assess the efficacy of virus-like particle (VLP) vaccine candidates containing stabilized pre-fusion (pre-F) or post-fusion (post-F) conformations of the RSV F protein and the attachment RSV G protein in a maternal immunization model using cotton rats. VLP vaccines containing RSV F and G proteins strongly boost pre-existing RSV immunity in dams preventing their perinatal drop in immunity. Boosting is stronger for the pre-F VLP than for the post-F VLP or purified subunit F protein vaccines, giving an advantage on mothers' protection. VLP immunization of dams provides significant protection to pups from RSV challenge and reduced pulmonary inflammation. Collectively, our results show that a VLP vaccine with RSV F and G proteins is safe and effective for maternal and adult vaccination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.